Navigation Links
EpiVax-Novozymes Tregitope-Albumin Fusion Moves 'Paradigm-Shifting' Treatment for Diabetes Closer to Clinical Trials
Date:2/12/2013

PROVIDENCE, R.I., Feb. 12, 2013 /PRNewswire/ -- EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering agent, albumin has excellent safety and pharmacokinetic profiles. Fusing Tregitopes to Novozymes' proven albumin-based half-life extension platform will create a safe and effective vehicle for the application of Tregitopes to multiple problems in the areas of autoimmunity, transplantation, and allergy.

(Logo: http://photos.prnewswire.com/prnh/20121116/NE15175LOGO )

Tregitopes, discovered by Anne De Groot and Bill Martin at EpiVax, are linear sequences of amino acids contained within the framework of monoclonal antibodies and immunoglobulin G; the original finding was published in the journal Blood in 2008. Since their discovery, EpiVax has compiled substantial evidence linking Tregitopes to the activation of natural regulatory T cells. By selectively activating these natural regulatory T cells, Tregitopes can dampen unwanted immune responses. Preliminary studies carried out by EpiVax and collaborators indicate that Tregitopes may be useful for inducing tolerance to transplants, protein drugs, and blood replacement therapies, as well as for the treatment of allergies. EpiVax believes Tregitopes may explain the effectiveness of intravenous immunoglobulin G (IVIG), widely utilized as an autoimmune treatment (a $4B annual market).

The initial disease target for Tregitope therapy with the albumin-Tregitope fusion will be Type 1 diabetes (T1D). Each year, more than 13,000 young people are diagnosed with T1D. Islet replacement therapy is in the experimental stage for individuals with advanced disease, and EpiVax believes the albumin-Tregitope fusion will facilitate this novel treatment for individuals in later stages of T1D.

Tregitopes act as a natural immune system "off switch" and have been shown in standard preclinical models to "reset" immune responses away from autoimmunity and towards tolerance. "Developing more specific therapies to promote tolerance … is a critical component of a comprehensive approach to T1D," said Julia L. Greenstein , Ph.D., VP of Cure Therapies for JDRF, whose previous funding helped EpiVax derive preliminary data to support recent NIH awards.  "[Tregitopes] may have the potential to reduce the harmful immune responses to the insulin-producing beta cells, thereby preserving the body's ability to make its own insulin." 

NIH SBIR grants coupled with private foundation funds have brought total pre-clinical funding for Tregitopes to more than $6M in the past 4 years.

FULL ARTICLE - http://bit.ly/EpiVaxNovoPR

Contact:
Anthony Marcello
1-401-272-2123
amarcello@epivax.com
www.epivax.com


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Launches New Take-Apart Laparoscopic Scissors
2. CareFusion Reports First Half Fiscal 2013 Results
3. CareFusion Files Fiscal 2012 Form 10-K
4. B. Braun Smart Infusion Pump Technology Advances Patient Safety and Treatment Efficiency
5. Global Spinal Nonfusion Market to Grow to $1 Billion by 2017, Despite Challenges
6. Hospira and Q Core Medical Sign International Distribution Agreement for Sapphire Infusion System
7. CareFusion Launches New Preoperative Cleansing Program For In-Home Patient Use
8. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
9. Practice Fusion Announces Free EMR for iPad in Beta
10. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
11. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):